What is Wedbush’s Estimate for Scholar Rock FY2028 Earnings?

Scholar Rock Holding Co. (NASDAQ:SRRK) – Equities research analysts at Wedbush increased their FY2028 earnings per share estimates for shares of Scholar Rock in a research note issued on Tuesday, November 12th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings of $0.39 per share for the year, up from their previous forecast of $0.33. Wedbush has a “Outperform” rating and a $37.00 price objective on the stock. The consensus estimate for Scholar Rock’s current full-year earnings is ($2.37) per share.

Other research analysts also recently issued reports about the stock. Piper Sandler increased their price objective on shares of Scholar Rock from $28.00 to $42.00 and gave the company an “overweight” rating in a research note on Tuesday, October 15th. JPMorgan Chase & Co. lifted their price target on Scholar Rock from $18.00 to $31.00 and gave the stock an “overweight” rating in a research note on Monday, October 14th. HC Wainwright upped their price objective on Scholar Rock from $35.00 to $40.00 and gave the company a “buy” rating in a research note on Tuesday. Finally, BMO Capital Markets lifted their target price on Scholar Rock from $34.00 to $38.00 and gave the stock an “outperform” rating in a research report on Friday, October 11th. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $34.00.

Scholar Rock Stock Down 3.7 %

SRRK stock opened at $26.49 on Thursday. The company has a current ratio of 3.88, a quick ratio of 6.04 and a debt-to-equity ratio of 0.63. The firm has a 50 day simple moving average of $20.61 and a 200-day simple moving average of $13.61. The company has a market capitalization of $2.48 billion, a P/E ratio of -11.27 and a beta of 0.47. Scholar Rock has a twelve month low of $6.76 and a twelve month high of $35.38.

Insider Activity

In related news, Director Srinivas Akkaraju sold 1,175,713 shares of Scholar Rock stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $29.25, for a total value of $34,389,605.25. Following the sale, the director now directly owns 5,612,896 shares in the company, valued at $164,177,208. This trade represents a 17.32 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Tracey Sacco sold 30,000 shares of the company’s stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $25.62, for a total transaction of $768,600.00. Following the completion of the transaction, the insider now owns 49,285 shares of the company’s stock, valued at approximately $1,262,681.70. This trade represents a 37.84 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 1,413,889 shares of company stock valued at $40,652,551. 19.20% of the stock is currently owned by insiders.

Institutional Trading of Scholar Rock

Several hedge funds have recently added to or reduced their stakes in SRRK. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Scholar Rock by 21.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,895 shares of the company’s stock valued at $25,000 after purchasing an additional 514 shares in the last quarter. American International Group Inc. lifted its position in Scholar Rock by 3.0% in the first quarter. American International Group Inc. now owns 28,407 shares of the company’s stock worth $505,000 after purchasing an additional 834 shares during the period. Rice Hall James & Associates LLC boosted its stake in Scholar Rock by 3.6% during the 2nd quarter. Rice Hall James & Associates LLC now owns 46,000 shares of the company’s stock valued at $383,000 after purchasing an additional 1,594 shares in the last quarter. ProShare Advisors LLC increased its position in shares of Scholar Rock by 11.7% during the 1st quarter. ProShare Advisors LLC now owns 15,412 shares of the company’s stock valued at $274,000 after purchasing an additional 1,620 shares during the period. Finally, ClariVest Asset Management LLC raised its stake in shares of Scholar Rock by 3.0% in the 2nd quarter. ClariVest Asset Management LLC now owns 59,640 shares of the company’s stock worth $497,000 after buying an additional 1,718 shares in the last quarter. Institutional investors own 91.08% of the company’s stock.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.